Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
PUBLIC CITIZEN: Senate Should Reject President’s Nominee to Be the Next FDA Commissioner
http://www.citizen.org/pressroom/pressroomredirect.cfm?ID=5635
Sept. 16, 2015
Senate Should Reject President’s Nominee to Be the Next FDA Commissioner
Statement of Dr. Michael Carome, Director, Public Citizen’s Health Research Group
The Senate should reject President Barack Obama’s nomination of Dr. Robert Califf to be the next commissioner of the U.S. Food and Drug Administration (FDA). His nomination undoubtedly comes as welcome news to the pharmaceutical and medical device manufacturers, but is bad news for patients and public health.
During his tenure at Duke University, Califf racked up a long history of extensive financial ties to multiple drug and medical device companies, including Amgen, AstraZeneca, Eli Lilly, Johnson & Johnson, Merck Sharp & Dohme and Sanofi-Aventis, to name a few. Strikingly, no FDA commissioner has had such close financial relationships with industries regulated by the agency prior to being appointed.
Califf’s appointment as FDA commissioner would accelerate a decades-long trend in which agency leadership too often makes decisions that are aligned more with the interests of industry, rather than those of public health and patients.
The Senate should reject Califf and demand that the president nominate someone who has not been so closely connected to FDA-regulated industries and is therefore better suited to protect public health.
Sept. 16, 2015
Senate Should Reject President’s Nominee to Be the Next FDA Commissioner
Statement of Dr. Michael Carome, Director, Public Citizen’s Health Research Group
The Senate should reject President Barack Obama’s nomination of Dr. Robert Califf to be the next commissioner of the U.S. Food and Drug Administration (FDA). His nomination undoubtedly comes as welcome news to the pharmaceutical and medical device manufacturers, but is bad news for patients and public health.
During his tenure at Duke University, Califf racked up a long history of extensive financial ties to multiple drug and medical device companies, including Amgen, AstraZeneca, Eli Lilly, Johnson & Johnson, Merck Sharp & Dohme and Sanofi-Aventis, to name a few. Strikingly, no FDA commissioner has had such close financial relationships with industries regulated by the agency prior to being appointed.
Califf’s appointment as FDA commissioner would accelerate a decades-long trend in which agency leadership too often makes decisions that are aligned more with the interests of industry, rather than those of public health and patients.
The Senate should reject Califf and demand that the president nominate someone who has not been so closely connected to FDA-regulated industries and is therefore better suited to protect public health.